Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
gptkb:cream
|
| gptkbp:approves |
gptkb:1996
gptkb:FDA |
| gptkbp:atccode |
S01 E E01
|
| gptkbp:available_on |
generic drug
|
| gptkbp:brand |
gptkb:Alphagan
gptkb:Alphagan_P |
| gptkbp:casnumber |
657-27-2
|
| gptkbp:chemical_formula |
C11 H10 Br N5
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:clinical_use |
long-term management of glaucoma
adjunct therapy with other glaucoma medications |
| gptkbp:contraindication |
gptkb:depression
severe cardiovascular disease hypersensitivity to brimonidine |
| gptkbp:developed_by |
gptkb:Allergan
|
| gptkbp:drug_interactions |
CNS depressants
MAO inhibitors tricyclic antidepressants antihypertensive medications |
| gptkbp:formulation |
0.1% solution
0.15% solution 0.2% solution |
| https://www.w3.org/2000/01/rdf-schema#label |
brimonidine
|
| gptkbp:invention |
patented
expires in 2020 |
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States |
| gptkbp:mechanism_of_action |
alpha-2 adrenergic agonist
|
| gptkbp:pharmacokinetics |
increases aqueous humor outflow
reduces intraocular pressure systemic absorption topical administration |
| gptkbp:provides_guidance_on |
used in combination therapy
recommended for first-line therapy |
| gptkbp:shelf_life |
typically 24 months
|
| gptkbp:side_effect |
fatigue
drowsiness dry mouth visual disturbances conjunctival hyperemia eyelid edema burning sensation in the eyes ocular allergic reactions |
| gptkbp:storage |
room temperature
protect from light |
| gptkbp:used_for |
gptkb:Ophthalmology
gptkb:ocular_hypertension |
| gptkbp:bfsParent |
gptkb:Alphagan
|
| gptkbp:bfsLayer |
7
|